The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | CM336: insights into a BCMAxCD3 bispecific antibody for AL amyloisosis from the AL-003 trial
Jieqiong Zhou, MD, China Yixueke Xueyuan Hemopathy Hospital, Tianjin, China, discusses the potential of CM336, a low-dose BCMA×CD3 bispecific antibody, in treating newly diagnosed systemic amyloid light chain (AL) amyloidosis, highlighting favorable hematological responses observed in the Phase II AL-003 trial (NCT07151690). Dr Zhou notes that CM336 may offer a more effective treatment option compared to standard therapies like daratumumab. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
